Parallel Advisors LLC Boosts Holdings in Gilead Sciences, Inc. $GILD

Parallel Advisors LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 111.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,470 shares of the biopharmaceutical company’s stock after acquiring an additional 39,239 shares during the quarter. Parallel Advisors LLC’s holdings in Gilead Sciences were worth $8,266,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Trivium Point Advisory LLC grew its holdings in Gilead Sciences by 1.1% during the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares during the last quarter. Rothschild Investment LLC boosted its position in shares of Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after buying an additional 84 shares during the period. Hemington Wealth Management boosted its position in shares of Gilead Sciences by 9.3% during the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 85 shares during the period. Ignite Planners LLC grew its stake in shares of Gilead Sciences by 1.1% during the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after buying an additional 86 shares during the last quarter. Finally, Archer Investment Corp grew its stake in shares of Gilead Sciences by 1.2% during the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after buying an additional 87 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the sale, the insider owned 120,288 shares in the company, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the sale, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at $25,910,110.97. The trade was a 1.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 309,280 shares of company stock worth $43,935,470. Company insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Scotiabank raised their price target on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Royal Bank Of Canada increased their target price on Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 11th. Wells Fargo & Company lifted their target price on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Barclays assumed coverage on shares of Gilead Sciences in a research note on Friday, February 20th. They set an “equal weight” rating and a $155.00 target price for the company. Finally, Argus lifted their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Twenty-three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $156.72.

Gilead Sciences Trading Down 0.7%

Shares of NASDAQ GILD opened at $144.08 on Friday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The firm has a market cap of $178.86 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 1.89 and a beta of 0.37. The business has a fifty day simple moving average of $138.29 and a two-hundred day simple moving average of $125.80. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.3%. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is currently 46.68%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.